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Abstract
© 2016, Iranian Society of Regional Anesthesia and Pain Medicine (ISRAPM). Context: Migraine
mechanisms remain largely uncovered for various reasons including a very high complexity of
the neurophysiological mechanisms implicated in this disorder and a plethora of endogenous
biologically  active  compounds  involved  in  the  pathological  process.  The  functional  role  of
parasympathetic innervation of meninges and cholinergic mechanisms of migraine are among
little explored issues despite multiple evidence i ndirectly indicating the role of acetylcholine
(ACh) and its analogues in migraine and other types of headache. In the current short review,
we discuss morphological,  functional,  and clinical issues related to the role of ACh and its
analogues such as carbachol and nicotine in this most common neurological disorder. Evidence
Acquisition:  In  the  present  work,  studies  published from 1953 to  2016 were  investigated.
Literature  was  searched  with  following  keywords:  acetylcholine  (ACh),  carbachol,  nicotine,
parasympathetic, mast cells, vasoactive intestinal polypeptide (VIP), and pituitary adenylate
cyclase-act ivat ing  polypeptide  (PACAP).  Results:  Parasympathetic  f ibers
originatedfromSPGandtrigeminal  nerves  can  interact  at  the  level  of  meninges  which  is
considered to be the origin site of migraine pain. Here, in dura mater, ACh, VIP, and PACAP
released by parasympathetic afferents can both affect mast cells provoking its degranulation
and  additional  release  of  neurotransmitters,  or  they  can  directly  affect  trigeminal  nerves
inducing nociception. Conclusions: In summary, cholinergic mechanisms in migraine and other
types  of  headache  remain  little  elucidated  and  future  studies  should  clarify  the  role  of
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